Medicine
Cefixime 200 mg/5 mL powder for oral suspension
Cefixime 200 mg/5 mL powder for oral suspension is a generic prescription medicine for oral use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store drug powder at 20° to 25°C (68° to 77°F). After Reconstitution: Store at…
Key facts
- Active ingredient (INN)
- Cefixime
- Brand
- Sold under the generic name
- Strength
- 200 mg/5 mL
- Dosage form
- Powder for oral suspension
- Route
- Oral
- Packs
- 50 mL, 75 mL and 1 more
- Manufacturers
- Aurobindo PharmaIndiaLupinIndia
- Origin register
- US FDA, United States
- Storage
- Store drug powder at 20° to 25°C (68° to 77°F). After Reconstitution: Store at room temperature or under refrigeration.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01DD08 Cefixime
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 April 2015
- Identifiers
- RxCUI 309058, 419849, 409823DailyMed set ID 068e6edd-a5fe-40d8-8dcf-ac82b78dced4, 6d68dbd9-7d75-4ff1-91db-79ff8ae879ecNDC 65862-752, 68180-407Application ANDA204835, ANDA065355
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 50 mL in 1 bottle | 65862-752-50 | Aurobindo PharmaIndia | 14 April 2015 |
| 75 mL in 1 bottle | 65862-752-75 | Aurobindo PharmaIndia | 14 April 2015 |
| 50 mL in 1 bottle | 68180-407-03 | LupinIndia | 24 April 2015 |
| 75 mL in 1 bottle | 68180-407-04 | LupinIndia | 24 April 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 April 1989 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cefixime
Clinical summary
Cefixime is a cephalosporin antibacterial indicated in the treatment of adults and pediatric patients six months and older with infections, among other approved uses. It is available as capsules, powder for oral suspension and tablets. MedsAcross supplies Cefixime for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CefiximeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CEFIXIME prescribing information (Lupin) · U.S. National Library of Medicine, DailyMed
Need Cefixime 200 mg/5 mL powder for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.